Logo image of SAN.PA

SANOFI (SAN.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:SAN - FR0000120578 - Common Stock

78.4 EUR
+0.37 (+0.47%)
Last: 1/21/2026, 7:00:00 PM
Fundamental Rating

4

Taking everything into account, SAN scores 4 out of 10 in our fundamental rating. SAN was compared to 54 industry peers in the Pharmaceuticals industry. SAN has a medium profitability rating, but doesn't score so well on its financial health evaluation. SAN is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year SAN was profitable.
  • In the past 5 years SAN has always been profitable.
  • SAN had a positive operating cash flow in each of the past 5 years.
SAN.PA Yearly Net Income VS EBIT VS OCF VS FCFSAN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

1.2 Ratios

  • With a decent Return On Assets value of 10.63%, SAN is doing good in the industry, outperforming 77.78% of the companies in the same industry.
  • SAN has a better Return On Equity (18.84%) than 64.81% of its industry peers.
  • SAN has a better Return On Invested Capital (13.40%) than 66.67% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for SAN is significantly below the industry average of 13.93%.
  • The last Return On Invested Capital (13.40%) for SAN is above the 3 year average (7.31%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 10.63%
ROE 18.84%
ROIC 13.4%
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
SAN.PA Yearly ROA, ROE, ROICSAN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • SAN's Profit Margin of 20.63% is fine compared to the rest of the industry. SAN outperforms 79.63% of its industry peers.
  • In the last couple of years the Profit Margin of SAN has grown nicely.
  • SAN's Operating Margin of 23.61% is in line compared to the rest of the industry. SAN outperforms 57.41% of its industry peers.
  • In the last couple of years the Operating Margin of SAN has grown nicely.
  • SAN has a Gross Margin of 72.29%. This is comparable to the rest of the industry: SAN outperforms 53.70% of its industry peers.
  • SAN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 23.61%
PM (TTM) 20.63%
GM 72.29%
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
SAN.PA Yearly Profit, Operating, Gross MarginsSAN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so SAN is still creating some value.
  • Compared to 1 year ago, SAN has about the same amount of shares outstanding.
  • SAN has about the same amout of shares outstanding than it did 5 years ago.
  • SAN has a better debt/assets ratio than last year.
SAN.PA Yearly Shares OutstandingSAN.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
SAN.PA Yearly Total Debt VS Total AssetsSAN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

  • SAN has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
  • SAN has a better Debt to Equity ratio (0.18) than 77.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z N/A
ROIC/WACC1.74
WACC7.72%
SAN.PA Yearly LT Debt VS Equity VS FCFSAN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.3 Liquidity

  • SAN has a Current Ratio of 1.06. This is a normal value and indicates that SAN is financially healthy and should not expect problems in meeting its short term obligations.
  • SAN has a Current ratio of 1.06. This is in the lower half of the industry: SAN underperforms 70.37% of its industry peers.
  • SAN has a Quick Ratio of 1.06. This is a bad value and indicates that SAN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of SAN (0.30) is worse than 88.89% of its industry peers.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 0.3
SAN.PA Yearly Current Assets VS Current LiabilitesSAN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

4

3. Growth

3.1 Past

  • The earnings per share for SAN have decreased by -5.35% in the last year.
  • SAN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.10% yearly.
  • Looking at the last year, SAN shows a small growth in Revenue. The Revenue has grown by 2.56% in the last year.
  • Measured over the past years, SAN shows a small growth in Revenue. The Revenue has been growing by 3.31% on average per year.
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%

3.2 Future

  • SAN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.41% yearly.
  • SAN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.47% yearly.
EPS Next Y2.37%
EPS Next 2Y5.23%
EPS Next 3Y5.91%
EPS Next 5Y7.41%
Revenue Next Year-0.09%
Revenue Next 2Y3.14%
Revenue Next 3Y4.36%
Revenue Next 5Y4.47%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SAN.PA Yearly Revenue VS EstimatesSAN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B 50B
SAN.PA Yearly EPS VS EstimatesSAN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8 10

5

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 10.32 indicates a reasonable valuation of SAN.
  • 85.19% of the companies in the same industry are more expensive than SAN, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of SAN to the average of the S&P500 Index (27.32), we can say SAN is valued rather cheaply.
  • The Price/Forward Earnings ratio is 9.22, which indicates a very decent valuation of SAN.
  • Based on the Price/Forward Earnings ratio, SAN is valued cheaper than 85.19% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 24.30. SAN is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 10.32
Fwd PE 9.22
SAN.PA Price Earnings VS Forward Price EarningsSAN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, SAN is valued a bit cheaper than 72.22% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.44
SAN.PA Per share dataSAN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SAN does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of SAN may justify a higher PE ratio.
PEG (NY)4.35
PEG (5Y)2.02
EPS Next 2Y5.23%
EPS Next 3Y5.91%

0

5. Dividend

5.1 Amount

  • SAN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

SANOFI

EPA:SAN (1/21/2026, 7:00:00 PM)

78.4

+0.37 (+0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-24
Earnings (Next)01-29
Inst Owners46.74%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap190.43B
Revenue(TTM)66.91B
Net Income(TTM)13.80B
Analysts79.31
Price Target101.26 (29.16%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend3.79
Dividend Growth(5Y)4.3%
DP34.36%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.79%
Min EPS beat(2)-2.29%
Max EPS beat(2)5.86%
EPS beat(4)2
Avg EPS beat(4)1.85%
Min EPS beat(4)-2.29%
Max EPS beat(4)6.02%
EPS beat(8)5
Avg EPS beat(8)3.19%
EPS beat(12)7
Avg EPS beat(12)2.67%
EPS beat(16)11
Avg EPS beat(16)3.3%
Revenue beat(2)0
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)-0.63%
Revenue beat(4)0
Avg Revenue beat(4)-1.95%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)-0.63%
Revenue beat(8)2
Avg Revenue beat(8)-1%
Revenue beat(12)4
Avg Revenue beat(12)9.01%
Revenue beat(16)8
Avg Revenue beat(16)21.12%
PT rev (1m)-5.92%
PT rev (3m)-7.67%
EPS NQ rev (1m)-3.33%
EPS NQ rev (3m)-9.74%
EPS NY rev (1m)-0.63%
EPS NY rev (3m)-1.68%
Revenue NQ rev (1m)0.14%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.72%
Revenue NY rev (3m)0.33%
Valuation
Industry RankSector Rank
PE 10.32
Fwd PE 9.22
P/S 2.85
P/FCF N/A
P/OCF N/A
P/B 2.6
P/tB 43.32
EV/EBITDA 10.44
EPS(TTM)7.6
EY9.69%
EPS(NY)8.5
Fwd EY10.85%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS27.54
BVpS30.16
TBVpS1.81
PEG (NY)4.35
PEG (5Y)2.02
Graham Number71.82
Profitability
Industry RankSector Rank
ROA 10.63%
ROE 18.84%
ROCE 16.17%
ROIC 13.4%
ROICexc 14.75%
ROICexgc 65.74%
OM 23.61%
PM (TTM) 20.63%
GM 72.29%
FCFM N/A
ROA(3y)5.02%
ROA(5y)6.2%
ROE(3y)8.55%
ROE(5y)10.84%
ROIC(3y)7.31%
ROIC(5y)7.07%
ROICexc(3y)8.13%
ROICexc(5y)7.97%
ROICexgc(3y)35.39%
ROICexgc(5y)35.54%
ROCE(3y)8.84%
ROCE(5y)8.55%
ROICexgc growth 3Y-13.63%
ROICexgc growth 5Y-1.43%
ROICexc growth 3Y-1.55%
ROICexc growth 5Y2.05%
OM growth 3Y-2.73%
OM growth 5Y1.75%
PM growth 3Y-7.54%
PM growth 5Y11.4%
GM growth 3Y0.71%
GM growth 5Y0.58%
F-ScoreN/A
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA 0.68
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.06
Quick Ratio 0.3
Altman-Z N/A
F-ScoreN/A
WACC7.72%
ROIC/WACC1.74
Cap/Depr(3y)73.02%
Cap/Depr(5y)67.36%
Cap/Sales(3y)6.35%
Cap/Sales(5y)5.97%
Profit Quality(3y)113.82%
Profit Quality(5y)104.22%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.35%
EPS 3Y5.45%
EPS 5Y5.1%
EPS Q2Q%1.75%
EPS Next Y2.37%
EPS Next 2Y5.23%
EPS Next 3Y5.91%
EPS Next 5Y7.41%
Revenue 1Y (TTM)2.56%
Revenue growth 3Y4.17%
Revenue growth 5Y3.31%
Sales Q2Q%-7.47%
Revenue Next Year-0.09%
Revenue Next 2Y3.14%
Revenue Next 3Y4.36%
Revenue Next 5Y4.47%
EBIT growth 1Y9.12%
EBIT growth 3Y1.33%
EBIT growth 5Y5.12%
EBIT Next Year29.1%
EBIT Next 3Y13.19%
EBIT Next 5Y10.5%
FCF growth 1Y-19.94%
FCF growth 3Y-11.46%
FCF growth 5Y-0.14%
OCF growth 1Y-11.47%
OCF growth 3Y-4.79%
OCF growth 5Y3.31%

SANOFI / SAN.PA FAQ

Can you provide the ChartMill fundamental rating for SANOFI?

ChartMill assigns a fundamental rating of 4 / 10 to SAN.PA.


Can you provide the valuation status for SANOFI?

ChartMill assigns a valuation rating of 5 / 10 to SANOFI (SAN.PA). This can be considered as Fairly Valued.


Can you provide the profitability details for SANOFI?

SANOFI (SAN.PA) has a profitability rating of 6 / 10.


What is the valuation of SANOFI based on its PE and PB ratios?

The Price/Earnings (PE) ratio for SANOFI (SAN.PA) is 10.32 and the Price/Book (PB) ratio is 2.6.


How financially healthy is SANOFI?

The financial health rating of SANOFI (SAN.PA) is 3 / 10.